Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates.
Kreuz
W
W
Johann Wolfgang Goethe University Hospital, Department of Paediatrics III (Haematology and Oncology), Centre of Haemophilia and Thrombosis, Frankfurt am Main, Germany.
Escuriola-Ettingshausen
C
C
Martinez-Saguer
I
I
Kaiml
M
M
Kornhuber
B
B
D001779:Blood Coagulation Factors / Q000037:antagonists & inhibitors* / Q000276:immunology; D002675:Child, Preschool; D005164:Factor IX / Q000037:antagonists & inhibitors / Q000276:immunology; D005169:Factor VIII / Q000037:antagonists & inhibitors / Q000276:immunology; D006467:Hemophilia A / Q000188:drug therapy / Q000453:epidemiology* / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D015994:Incidence; D007223:Infant; D007518:Isoantibodies / Q000009:adverse effects / Q000097:blood / Q000187:drug effects; D015995:Prevalence
D001779:Blood Coagulation Factors; D007518:Isoantibodies; C025667:prothrombin complex concentrates; D005169:Factor VIII; D005164:Factor IX